BioStem Technologies, Inc. (OTC: BSEM), a regenerative medicine company specializing in perinatal tissue allografts, announced today that it will release its first quarter 2026 financial results on Thursday, May 14, 2026. The company will host a conference call and webcast at 4:30 PM ET on the same day to discuss the results and provide a business update.
The webcast will feature an overview of the quarter from BioStem Technologies management. Investors and interested parties can register for the event by clicking here. The conference call can be accessed via toll-free dial-in at (800) 715-9871 (North America) or +1 (646) 307-1963 (international), using conference ID 9695874.
BioStem Technologies is a biomedical innovator focused on developing, manufacturing, and commercializing advanced allograft solutions derived from perinatal tissue. The company leverages proprietary processing technologies—BioRetain®, CryoTek®, and SteriTek®—designed to preserve the natural properties of tissues for clinical use. Its allografts are used across various medical specialties. The company's quality management system is accredited by the American Association of Tissue Banks (AATB) and complies with current Good Tissue Practices (cGTP) and current Good Manufacturing Processes (cGMP).
BioStem's portfolio includes the Neox®, Clarix®, VENDAJE®, and American Amnion™ product lines. The company has a growing portfolio of products, expanding clinical research initiatives, and a national commercial footprint. For the latest news and updates regarding $BSEM, visit the company's newsroom at https://tinyurl.com/bsemnewsroom.
The upcoming financial results release comes as BioStem continues to advance its position in the regenerative medicine market. Investors will be looking for updates on revenue growth, product adoption, and clinical developments during the call. The company's focus on perinatal tissue allografts addresses a growing demand for minimally invasive treatment options in wound care, orthopedics, and surgical recovery.
